article · Journal of Fluorescence
Abstract Semaglutide (SEMG) is one of the most widely used and trending medications to treat type II diabetes and obesity. This work aimed to develop a liquid chromatography with spectroflourimetric detection (HPLC-flourimetry) analysis of SEMG in both its tablet dosage form and plasma. The power of fluorescence detection coupled with HPLC proved its capability as a bioanalytical tool to assay SEMG in plasma samples owing to its simplicity and sensitivity which reached below the C max of SEMG. Separation was done using a C 18 column with mobile phase of acetonitrile and water acidified with orthophosphoric acid (pH 3.5) (1.41 × 10 –5 M) in isocratic mode in ratio 57:43 and 1 mL/min flow rate after extraction using protein precipitation. Detection was carried out at λ excitation of 238 nm and λ emission of 416 and 307 nm for SEMG and the internal standard, respectively. Evaluation of greenness of the proposed method was done using AGREE (Analytical GREEnness Metric Approach), ComplexGAPI (Complementary Green Analytical Procedure Index) & the new algorithm RGB 12 model (Red–Green–Blue). They showed that these methods can be a greener alternative with acceptable sensitivity for analysis of SEMG. The developed seven min-assay was validated per ICH as well as FDA bio analytical methods’ guidelines to prove its applicability for routine sample analysis and future pharmacokinetic studies.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s10895-024-03954-9
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.